Raj K Maturi
Overview
Explore the profile of Raj K Maturi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Macha N, Yu M, Sapieha P, Klier S, Ghosh A, White L, et al.
J Clin Med
. 2024 Sep;
13(18).
PMID: 39337030
: The objective of this study was to determine the treatment effect of foselutoclax in neovascular age-related macular degeneration (AMD) by multifocal electroretinography (mfERG) and evaluate mfERG as a potential...
2.
Burgett L, Aggarwal N, Latona J, Driban M, Chhablani J, Maturi R
J Vitreoretin Dis
. 2024 Sep;
8(5):508-516.
PMID: 39318981
To evaluate a large database detailing the changes in visual acuity (VA) and central subfield thickness after various treatments for central serous chorioretinopathy (CSCR). A retrospective analysis was performed of...
3.
Jhaveri C, Liu D, Maguire M, Glassman A, Grigorian R, Jampol L, et al.
Ophthalmology
. 2024 Feb;
131(8):967-974.
PMID: 38336282
Purpose: To identify factors for meeting prespecified criteria for switching from bevacizumab to aflibercept in eyes with center-involved diabetic macular edema (CI-DME) and moderate vision loss initially treated with bevacizumab...
4.
Pereira D, Maturi R, Akita K, Mahesh V, Bhisitkul R, Nishihata T, et al.
Eye (Lond)
. 2023 Nov;
38(6):1140-1148.
PMID: 38036609
Background/objective: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative age-related macular degeneration (nAMD). Due to the limitations of these standard therapies, targeting alternative...
5.
6.
Callanan D, Khurana R, Maturi R, Patel S, Wykoff C, Eichenbaum D, et al.
Clin Ophthalmol
. 2023 May;
17:1367-1384.
PMID: 37197577
Purpose: To evaluate the impact of modifying the abicipar pegol (abicipar) manufacturing process on the safety and treatment effect of abicipar in patients with neovascular age-related macular degeneration (nAMD). Methods:...
7.
Maturi R, Glassman A, Josic K, Baker C, Gerstenblith A, Jampol L, et al.
JAMA
. 2023 Feb;
329(5):376-385.
PMID: 36749332
Importance: Anti-vascular endothelial growth factor (VEGF) injections in eyes with nonproliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME) reduce development of vision-threatening complications from diabetes over at least...
8.
Sun J, Beaulieu W, Melia M, Ferris 3rd F, Maturi R, Nielsen J, et al.
Retina
. 2023 Feb;
43(4):616-623.
PMID: 36728692
Background/purpose: To define "strong" versus "weak" antivascular endothelial growth factor (anti-VEGF) treatment response in eyes with center-involved diabetic macular edema (CI-DME). Methods: Exploratory analyses of three DRCR Retina Network randomized...
9.
Rowe L, Minturn R, Burgett L, Bracha P, Maturi R
Int J Retina Vitreous
. 2023 Jan;
9(1):1.
PMID: 36604756
Background: To determine the safety and efficacy of intravitreal sirolimus and adjunct aflibercept in subjects with persistent, exudative age-related macular degeneration despite previous intravitreal anti-vascular endothelial growth factor (VEGF) treatment....
10.
Khanani A, Maturi R, Bagheri N, Bakall B, Boyer D, Couvillion S, et al.
Ophthalmol Sci
. 2022 Oct;
2(2):100154.
PMID: 36249705
Purpose: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD)...